Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
While they can’t predict the future, financial advisors are placing their bets on active investments, quantum computing, and more.
As retail investors booms, advisors are balancing full-service offerings with more hands-on advice options.
Investors have plenty of choices to gain exposure to the Magnificent 7, depending on how much risk or reward they choose to take.